These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds. Matter H; Scheiper B; Steinhagen H; Böcskei Z; Fleury V; McCort G Bioorg Med Chem Lett; 2011 Sep; 21(18):5487-92. PubMed ID: 21840215 [TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors. Scheiper B; Matter H; Steinhagen H; Stilz U; Böcskei Z; Fleury V; McCort G Bioorg Med Chem Lett; 2010 Nov; 20(21):6268-72. PubMed ID: 20850300 [TBL] [Abstract][Full Text] [Related]
9. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors. Wang A; Prouty CP; Pelton PD; Yong M; Demarest KT; Murray WV; Kuo GH Bioorg Med Chem Lett; 2010 Feb; 20(4):1432-5. PubMed ID: 20089400 [TBL] [Abstract][Full Text] [Related]
12. Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors. Scheiper B; Matter H; Steinhagen H; Böcskei Z; Fleury V; McCort G Bioorg Med Chem Lett; 2011 Sep; 21(18):5480-6. PubMed ID: 21840218 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416 [TBL] [Abstract][Full Text] [Related]
14. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation. DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and preliminary biological evaluation of 2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine derivatives. Jiao PF; Zhao BX; Wang WW; He QX; Wan MS; Shin DS; Miao JY Bioorg Med Chem Lett; 2006 Jun; 16(11):2862-7. PubMed ID: 16563757 [TBL] [Abstract][Full Text] [Related]
16. Optimization of a series of multi-isoform PI3 kinase inhibitors. Perry B; Beevers R; Bennett G; Buckley G; Crabbe T; Gowers L; James L; Jenkins K; Lock C; Sabin V; Wright S Bioorg Med Chem Lett; 2008 Oct; 18(19):5299-302. PubMed ID: 18774713 [TBL] [Abstract][Full Text] [Related]
17. Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines. Perry B; Alexander R; Bennett G; Buckley G; Ceska T; Crabbe T; Dale V; Gowers L; Horsley H; James L; Jenkins K; Crépy K; Kulisa C; Lightfoot H; Lock C; Mack S; Morgan T; Nicolas AL; Pitt W; Sabin V; Wright S Bioorg Med Chem Lett; 2008 Aug; 18(16):4700-4. PubMed ID: 18644721 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors. Wang L; Wang GT; Wang X; Tong Y; Sullivan G; Park D; Leonard NM; Li Q; Cohen J; Gu WZ; Zhang H; Bauch JL; Jakob CG; Hutchins CW; Stoll VS; Marsh K; Rosenberg SH; Sham HL; Lin NH J Med Chem; 2004 Jan; 47(3):612-26. PubMed ID: 14736242 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. Terasaka T; Okumura H; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Seki N; Naoe Y; Inoue T; Tanaka K; Nakamura K J Med Chem; 2004 May; 47(11):2728-31. PubMed ID: 15139750 [TBL] [Abstract][Full Text] [Related]
20. The discovery and synthesis of potent zwitterionic inhibitors of renin. Aspiotis R; Chen A; Cauchon E; Dubé D; Falgueyret JP; Gagné S; Gallant M; Grimm EL; Houle R; Juteau H; Lacombe P; Laliberté S; Lévesque JF; MacDonald D; McKay D; Percival MD; Roy P; Soisson SM; Wu T Bioorg Med Chem Lett; 2011 Apr; 21(8):2430-6. PubMed ID: 21429746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]